Our results indicated that downregulated miR‐138‐5p strengthened mitochondrial biogenesis through targeting MCU, thus contributing to CRC cell growth, which may provide a potential therapeutic target for CRC. The gene discussed is MCU; the disease is colorectal carcinoma.